Upregulation of Wnt/β-catenin has been shown to be a mechanism of resistance to PI3K inhibitors, and the use of β-catenin inhibitors may sensitize PIK3CA mutant breast cancer to PI3K inhibition [37]. The gene discussed is PIK3CA; the disease is breast carcinoma.